

# Angelo Dei Tos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2983426/publications.pdf>

Version: 2024-02-01

219  
papers

13,657  
citations

28274

55  
h-index

23533

111  
g-index

222  
all docs

222  
docs citations

222  
times ranked

13245  
citing authors

#	ARTICLE	IF	CITATIONS
1	Beware of Histiocytes: Whipple Adenopathy and its Mimics. <i>International Journal of Surgical Pathology</i> , 2022, 30, 163-166.	0.8	0
2	Clinical implications of alpha, beta, and gamma HPV infection in juvenile onset recurrent respiratory papillomatosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 285-292.	1.6	4
3	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 939-944.	2.8	3
4	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISGASTS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	4.1	46
5	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
6	Relevance of bone marrow histology in challenging cases of Acute Myeloid Leukemia. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	1.3	0
7	Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions. <i>Surgery</i> , 2022, 171, 1605-1611.	1.9	1
8	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Cancers</i> , 2022, 14, 338.	3.7	2
9	Necrotizing Follicular Lymphoma of the Inguinal Region with Sternbergoid Cells: Clinical-Pathological Features of a Challenging Entity. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1290.	2.5	0
10	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. <i>Frontiers in Endocrinology</i> , 2022, 13, 834075.	3.5	5
11	Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases. <i>Current Oncology</i> , 2022, 29, 1455-1460.	2.2	1
12	Multi-Design Differential Expression Profiling of COVID-19 Lung Autopsy Specimens Reveals Significantly Deregulated Inflammatory Pathways and SFTPC Impaired Transcription. <i>Cells</i> , 2022, 11, 1011.	4.1	5
13	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	2.3	1
14	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. <i>European Journal of Cancer</i> , 2022, 166, 165-175.	2.8	17
15	Of drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
16	Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia. <i>British Journal of Haematology</i> , 2022, 198, 916-922.	2.5	6
17	Clear cell sarcoma-like/malignant gastrointestinal neuroectodermal tumor of the tongue: a clinicopathologic and molecular case report. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1203-1207.	2.8	8
18	Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. <i>Tumori</i> , 2021, 107, 46-54.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. <i>Leukemia</i> , 2021, 35, 984-1000.	7.2	12
20	Histology of the spleen in immune thrombocytopenia: clinical and pathological characterization and prognostic implications. <i>European Journal of Haematology</i> , 2021, 106, 281-289.	2.2	4
21	Detection of HPV16 /18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay. <i>Laryngoscope</i> , 2021, 131, 1042-1048.	2.0	6
22	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case series analysis within the Italian Rare Cancer Network. <i>Cancer</i> , 2021, 127, 569-576.	4.1	24
23	The Immunopathological and Histological Landscape of COVID-19-Mediated Lung Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 974.	4.1	25
24	Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. <i>European Journal of Haematology</i> , 2021, 106, 737-739.	2.2	10
25	“While there is p57, there is hope.” The past and the present of diagnosis in first trimester abortions: Diagnostic dilemmas and algorithmic approaches. A review. <i>Placenta</i> , 2021, 116, 31-37.	1.5	5
26	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	2.8	8
27	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 627527.	2.8	4
28	Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling. <i>Genes</i> , 2021, 12, 481.	2.4	13
29	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	3.7	12
30	Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1897-1904.	2.5	7
31	Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, , 1.	2.8	0
32	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021, 16, 517-527.	3.6	7
33	Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. <i>Pathology Research and Practice</i> , 2021, 221, 153451.	2.3	30
34	Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology. <i>Frontiers in Oncology</i> , 2021, 11, 663221.	2.8	2
35	Lymph node core needle biopsy in lymphoproliferative disorders” Authors’ reply to Al-Abbadi and colleagues. <i>European Journal of Haematology</i> , 2021, 107, 297-298.	2.2	2
36	Mesenchymal tumours of the gastrointestinal tract. <i>Pathologica</i> , 2021, 113, 230-251.	3.4	14

#	ARTICLE	IF	CITATIONS
37	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. <i>JCO Precision Oncology</i> , 2021, 5, 1166-1177.	3.0	55
38	Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1778-1783.	1.0	5
39	mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs. <i>Endocrine-Related Cancer</i> , 2021, 28, 449-456.	3.1	3
40	The Rarest of Rare Thymic Lesions: A 10-Year Surgical Pathology Experience. <i>Cancers</i> , 2021, 13, 4056.	3.7	1
41	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	4.1	2
42	The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. <i>Pathologica</i> , 2021, 113, 70-84.	3.4	322
43	RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study. <i>Frontiers in Oncology</i> , 2021, 11, 728319.	2.8	2
44	Protein Kinase CK1 $\delta$ Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 733848.	2.8	4
45	Intra-Articular Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 665-677.	1.7	1
46	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 1095.	2.5	42
47	The contribution of Juan Rosai to the pathology of soft tissue tumors. <i>Pathologica</i> , 2021, 113, 396-409.	3.4	1
48	The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. <i>Cancers</i> , 2021, 13, 5666.	3.7	11
49	TERT Promoter Mutations and rs2853669 Polymorphism: Useful Markers for Clinical Outcome Stratification of Patients With Oral Cavity Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 782658.	2.8	8
50	Ewing sarcoma and Ewing-like tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 109-119.	2.8	121
51	Multifocal Medulloblastoma in an Adult Patient: Description of a Rare Presentation and Review of the Literature. <i>Case Reports in Pathology</i> , 2020, 2020, 1-6.	0.3	1
52	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' Italiana di Ginecologia e Obstetrica). <i>Journal of Obstetrics and Gynaecology</i> , 2020, 2020, 1-6.	2.8	21
53	Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. <i>ESMO Open</i> , 2020, 5, e000843.	4.5	14
54	Spermatic Cord Sarcoma: A 20-Year Single-Institution Experience. <i>Frontiers in Surgery</i> , 2020, 7, 566408.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	1.6	145
56	Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions. <i>Frontiers in Oncology</i> , 2020, 10, 828.	2.8	14
57	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	4.5	11
58	Feasibility of postmortem examination in the era of COVID-19 pandemic: the experience of a Northeast Italy University Hospital. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 341-347.	2.8	38
59	Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 5534-5538.	7.0	15
60	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	3.7	77
61	TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 381-389.	2.5	15
62	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489.	2.8	38
63	Primary malignant ossifying fibromyxoid tumour of the bone. A clinicopathologic and molecular report of two cases. <i>Pathologica</i> , 2020, 112, 184-190.	3.4	3
64	Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11533-11533.	1.6	0
65	The pathology of soft tissue sarcomas. <i>Radiologia Medica</i> , 2019, 124, 266-281.	7.7	35
66	Absence of disruptive TP53 mutations in high-risk human papillomavirus-driven neck squamous cell carcinoma of unknown primary. <i>Head and Neck</i> , 2019, 41, 3833-3841.	2.0	2
67	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
68	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019, 109, 51-60.	2.8	134
69	Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. <i>Human Pathology</i> , 2019, 91, 11-18.	2.0	20
70	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	7.0	70
71	Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019, 9, 35-43.	7.1	49
72	Primary vascular bone tumors in the spine: a challenge for pathologists and spine oncology surgeons. <i>European Spine Journal</i> , 2019, 28, 1502-1511.	2.2	10

#	ARTICLE	IF	CITATIONS
73	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	7.0	67
74	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	3.7	26
75	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	7.1	42
76	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11000-11000.	1.6	4
77	Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11066-11066.	1.6	2
78	Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).. <i>Journal of Clinical Oncology</i> , 2019, 37, e22545-e22545.	1.6	3
79	Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11065-11065.	1.6	1
80	Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22540-e22540.	1.6	0
81	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 93, 28-36.	2.8	49
82	Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor. <i>Anti-Cancer Drugs</i> , 2018, 29, 589-595.	1.4	10
83	Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. <i>Modern Pathology</i> , 2018, 31, 160-168.	5.5	4
84	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. <i>European Journal of Cancer</i> , 2018, 105, 19-27.	2.8	56
85	A Pediatric Intra-Axial Malignant SMARCB1-Deficient Desmoplastic Tumor Arising in Meningioangiomatosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 883-889.	1.7	7
86	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	10.7	61
87	Identification of an Actionable Mutation of KIT in a Case of Extraskelatal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	4.1	4
88	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3590-3590.	1.6	4
89	Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant versus 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10yr median FU.. <i>Journal of Clinical Oncology</i> . 2018. 36. 11558-11558.	1.6	0
90	Doxorubicin (D), gemcitabine (G), ifosfamide (I) and the EZH2 inhibitor EPZ-011989 in epithelioid sarcoma (ES): A comparison of different regimens in a patient-derived xenograft (PDX) model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11578-11578.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC).. Journal of Clinical Oncology, 2018, 36, 11561-11561.	1.6	0
92	Impact of pathological stratification of advanced well differentiated/dedifferentiated (WD/DD) liposarcoma (LPS) on the response to trabectedin (T).. Journal of Clinical Oncology, 2018, 36, 11566-11566.	1.6	1
93	Identification of an actionable mutation of <i>KIT</i> in extraskeletal myxoid chondrosarcoma (EMC).. Journal of Clinical Oncology, 2018, 36, e23547-e23547.	1.6	0
94	FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 11556-11556.	1.6	1
95	Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. Clinical Cancer Research, 2017, 23, 273-282.	7.0	66
96	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
97	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	10.7	370
98	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. European Journal of Cancer, 2017, 78, 122-132.	2.8	28
99	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. British Journal of Cancer, 2017, 117, 340-346.	6.4	20
100	Soft Tissue Tumors Rarely Presenting Primary in Bone; Diagnostic Pitfalls. Surgical Pathology Clinics, 2017, 10, 705-730.	1.7	20
101	The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness. PLoS Genetics, 2017, 13, e1006752.	3.5	38
102	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget, 2017, 8, 60036-60045.	1.8	17
103	Characterization of malignant gastrointestinal stromal tumorsâ€”a single center experience. Journal of Gastrointestinal Oncology, 2017, 8, 1037-1045.	1.4	7
104	<i>CIC</i> â€” <i>DUX4</i> fusionâ€”positive roundâ€”cell sarcomas of soft tissue and bone: a singleâ€”institution morphological and molecular analysis of seven cases. Histopathology, 2016, 69, 624-634.	2.9	73
105	Transcriptome sequencing identifies <i>ETV6</i> â€” <i>NTRK3</i> as a gene fusion involved in GIST. Journal of Pathology, 2016, 238, 543-549.	4.5	156
106	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncology, The, 2016, 17, 671-680.	10.7	318
107	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelialâ€”Mesenchymal Transitionâ€”like Process and 22q Loss. Molecular Cancer Research, 2016, 14, 820-829.	3.4	25
108	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clinical Sarcoma Research, 2016, 6, 15.	2.3	80

#	ARTICLE	IF	CITATIONS
109	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	1.5	56
110	Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor. <i>Medicine (United States)</i> , 2016, 95, 107-110.	1.0	17
111	Paediatric chondrosarcomas: a retrospective review of 17 cases. <i>Histopathology</i> , 2016, 68, 1073-1078.	2.9	10
112	Imatinib-Sensitizing <i>KIT</i> Mutation in a Carney-Stratakis-Associated GI Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2016, 34, e99-e103.	1.6	12
113	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	7.0	78
114	Head and Neck Extranodal Interdigitating Dendritic Cell Sarcoma: Case Report and Review of the Literature. <i>Head and Neck Pathology</i> , 2016, 10, 145-151.	2.6	18
115	Imatinib dose escalation versus sunitinib as a second line treatment in <i>KIT</i> exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	1.8	17
116	Concomitant <i>KIT</i> / <i>BRAF</i> and <i>PDGFRA</i> / <i>BRAF</i> mutations are rare events in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 30109-30118.	1.8	25
117	Small Cell Osteosarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 691-699.	3.7	49
118	Impact of fecal immunochemical test-based screening programs on proximal and distal colorectal cancer surgery rates: A natural multiple-baseline experiment. <i>Cancer</i> , 2015, 121, 3982-3989.	4.1	7
119	<i>KIT</i> , <i>PDGFRA</i> , and <i>BRAF</i> Mutational Spectrum Impacts on the Natural History of Imatinib-naïve Localized GIST. <i>American Journal of Surgical Pathology</i> , 2015, 39, 922-930.	3.7	63
120	Trabectedin in advanced synovial sarcomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 678-681.	1.4	44
121	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	3.7	101
122	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	1.6	148
123	Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e66-e70.	1.6	5
124	Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. <i>Gut</i> , 2015, 64, 784-790.	12.1	231
125	Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. <i>Oncology</i> , 2015, 89, 1-13.	1.9	24
126	Broadening the spectrum of <i>SMARCB1</i> -associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosis. <i>Human Pathology</i> , 2015, 46, 1226-1231.	2.0	10



#	ARTICLE	IF	CITATIONS
127	Primary pseudomyogenic haemangioendothelioma of bone: report of two cases. <i>Skeletal Radiology</i> , 2015, 44, 727-731.	2.0	31
128	Classic Kaposi Sarcoma: to treat or not to treat?. <i>BMC Research Notes</i> , 2015, 8, 138.	1.4	8
129	Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases. <i>Clinical Sarcoma Research</i> , 2015, 5, 7.	2.3	39
130	Reagent and Labor Cost Optimization through Automation of Fluorescence In Situ Hybridization (FISH) with the VP 2000: An Italian Case Study. <i>Journal of the Association for Laboratory Automation</i> , 2015, 20, 25-31.	2.8	6
131	Deregulation of dicer and mir-155 expression in liposarcoma. <i>Oncotarget</i> , 2015, 6, 10586-10591.	1.8	21
132	Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. <i>Oncotarget</i> , 2015, 6, 43472-43482.	1.8	30
133	H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1376-E1380.	3.6	42
134	High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 16.	2.3	44
135	Challenging epithelioid mesenchymal neoplasms: mimics and traps. <i>Pathology</i> , 2014, 46, 126-134.	0.6	7
136	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 249-259.	4.1	30
137	Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot. <i>International Journal of Vascular Medicine</i> , 2014, 2014, 1-7.	1.0	10
138	Lipofibromatosis: magnetic resonance imaging features and pathological correlation in three cases. <i>Skeletal Radiology</i> , 2014, 43, 633-639.	2.0	20
139	Anaplastic ependymoma of the third ventricle. <i>Brain Tumor Pathology</i> , 2014, 31, 274-281.	1.7	5
140	Liposarcomas: diagnostic pitfalls and new insights. <i>Histopathology</i> , 2014, 64, 38-52.	2.9	144
141	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	2.8	80
142	Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. <i>Clinical Sarcoma Research</i> , 2013, 3, 4.	2.3	81
143	Spinal extradural solitary fibrous tumor with retiform and papillary features. <i>Annals of Diagnostic Pathology</i> , 2013, 17, 281-287.	1.3	11
144	The role of the pathologist in the decision-making process. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 23-26.	2.2	3

#	ARTICLE	IF	CITATIONS
145	A current perspective on the role for molecular studies in soft tissue tumor pathology. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 375-381.	1.5	18
146	Targeted Therapies in Rare Sarcomas. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1049-1061.	2.2	18
147	On the prevalence of KRAS mutations in GISTs. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 847-847.	2.8	4
148	Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1-7.	4.1	13
149	Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 7-10.	0.6	6
150	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. <i>European Journal of Cancer</i> , 2013, 49, 2565-2578.	2.8	91
151	GISTogram: a graphic presentation of the growing GIST complexity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 481-487.	2.8	26
152	The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1433-1440.	3.7	75
153	Myxoid liposarcoma and the mammalian target of rapamycin pathway. <i>Current Opinion in Oncology</i> , 2013, 25, 379-383.	2.4	13
154	Impact of Molecular Analysis on the Final Sarcoma Diagnosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1259-1268.	3.7	55
155	<i>SMARCB1</i> Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1060-1072.	4.1	46
156	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	1.6	156
157	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2012, 379, 1879-1886.	13.7	1,752
158	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. <i>Lancet Oncology, The</i> , 2012, 13, 265-274.	10.7	790
159	Pazopanib for metastatic soft-tissue sarcoma – Authors' reply. <i>Lancet, The</i> , 2012, 380, 801.	13.7	4
160	Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 561-570.	2.8	78
161	Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. <i>BMC Health Services Research</i> , 2012, 12, 82.	2.2	57
162	Platelet-derived growth factor receptor alpha expression improves the diagnostic assessment of gastrointestinal stromal tumours. <i>Histopathology</i> , 2012, 61, 1240-1245.	2.9	1

#	ARTICLE	IF	CITATIONS
163	The clinical impact of molecular techniques on diagnostic pathology of soft tissue and bone tumours. <i>Diagnostic Histopathology</i> , 2012, 18, 81-85.	0.4	2
164	Clear Cell Sarcoma of the Ileum. <i>International Journal of Surgical Pathology</i> , 2012, 20, 401-406.	0.8	24
165	Incidence of soft tissue sarcoma and beyond. <i>Cancer</i> , 2012, 118, 5339-5348.	4.1	210
166	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	4.1	85
167	Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. <i>Medical Oncology</i> , 2012, 29, 144-150.	2.5	7
168	A Small Intraneural Epithelioid Malignant Peripheral Nerve Sheath Tumour of the Median Nerve Simulating a Benign Lesion. Description of a Case and Review of the Literature. <i>Pathology and Oncology Research</i> , 2012, 18, 101-106.	1.9	1
169	Rare cancers are not so rare: The rare cancer burden in Europe. <i>European Journal of Cancer</i> , 2011, 47, 2493-2511.	2.8	573
170	Gastrointestinal stromal tumors: The histology report. <i>Digestive and Liver Disease</i> , 2011, 43, S304-S309.	0.9	21
171	Clinical application of molecular pathology in sarcomas. <i>Current Opinion in Oncology</i> , 2011, 23, 379-384.	2.4	15
172	Natural History of Imatinib-naive GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1646-1656.	3.7	116
173	Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2011, 59, 1071-1080.	2.9	22
174	Intramedullary malignant peripheral nerve sheath tumor. <i>Journal of Neuro-Oncology</i> , 2011, 105, 441-443.	2.9	1
175	Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers. <i>Journal of Pathology</i> , 2011, 223, 565-566.	4.5	10
176	Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1480-1491.	3.7	114
177	The Marriage Between Pathology and Genetics: Are We Ready for Clinical Use?. <i>Annals of Surgical Oncology</i> , 2010, 17, 668-669.	1.5	0
178	Soft tissue tumors associated with EWSR1 translocation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 219-234.	2.8	149
179	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. <i>Histopathology</i> , 2010, 57, 259-270.	2.9	162
180	Adipocytic Tumors. , 2010, , 97-118.		3

#	ARTICLE	IF	CITATIONS
181	Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells. PLoS ONE, 2010, 5, e14154.	2.5	54
182	Primary leptomeningeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. Acta Neuropathologica, 2009, 118, 575-577.	7.7	23
183	Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy. Human Pathology, 2009, 40, 1040-1044.	2.0	1
184	The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets?. Lung Cancer, 2009, 65, 49-55.	2.0	40
185	Benign Cartilaginous Tumors of Bone. Advances in Anatomic Pathology, 2009, 16, 307-315.	4.3	59
186	Primary cardiac onset of disseminated Burkitt's lymphoma. Annals of Hematology, 2008, 87, 487-488.	1.8	4
187	Desmoid-type fibromatosis: from morphology to molecular genetics. Diagnostic Histopathology, 2008, 14, 546-551.	0.4	8
188	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. Clinical Breast Cancer, 2008, 8, 436-442.	2.4	25
189	Atypical cystic meningioma overexpressing AQP1 in early infancy: case report with literature review. Acta Paediatrica, International Journal of Paediatrics, 2008, 97, 1145-1149.	1.5	6
190	Aleukemic granulocytic sarcoma with associated T-cell lymphoblastic lymphoma in the same lymph node: Morphologic features and molecular signatures. Leukemia and Lymphoma, 2008, 49, 1411-1415.	1.3	2
191	<i>EWSR1-CREB1</i> and <i>EWSR1-ATF1</i> Fusion Genes in Angiomatoid Fibrous Histiocytoma. Clinical Cancer Research, 2007, 13, 7322-7328.	7.0	207
192	Chromosomal Imbalances and Cytogenetic Progression in Gastrointestinal Stromal Tumor. Advances in Anatomic Pathology, 2007, 14, 301-302.	4.3	0
193	Advances in Gastrointestinal Stromal Tumor Therapy. Advances in Anatomic Pathology, 2007, 14, 302.	4.3	0
194	Cell Membrane Reactivity of MIB-1 Antibody to Ki67 in Human Tumors: Fact or Artifact?. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 220-223.	1.2	74
195	Small round-cell neoplasms of soft tissues: An integrated diagnostic approach. Current Diagnostic Pathology, 2007, 13, 150-163.	0.4	12
196	Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: Evidence of simultaneous expansion of two independent clones. Leukemia and Lymphoma, 2006, 47, 885-889.	1.3	18
197	Myopericytoma of Skin and Soft Tissues. American Journal of Surgical Pathology, 2006, 30, 104-113.	3.7	279
198	Estrogen receptor- $\beta$ is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Modern Pathology, 2006, 19, 599-606.	5.5	74

#	ARTICLE	IF	CITATIONS
199	Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 148-157.	1.3	118
200	Morphologic and Immunophenotypic Diversity in Ewing Family Tumors. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1025-1033.	3.7	376
201	Rabbit Monoclonal Antibodies: A Comparative Study Between a Novel Category of Immunoreagents and the Corresponding Mouse Monoclonal Antibodies. <i>American Journal of Clinical Pathology</i> , 2005, 124, 295-302.	0.7	61
202	Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1025-33.	3.7	267
203	Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. <i>Modern Pathology</i> , 2004, 17, 547-552.	5.5	218
204	Squamous cell carcinoma arising in a ciliated hepatic foregut cyst. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 296-298.	2.8	87
205	Primary Peripheral PNET/Ewing's Sarcoma of the Dura: a Clinicopathologic Entity Distinct from Central PNET. <i>Modern Pathology</i> , 2002, 15, 673-678.	5.5	86
206	Morphological Analysis of Nevoid Melanoma. <i>American Journal of Dermatopathology</i> , 2001, 23, 167-175.	0.6	113
207	Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. <i>Neurogenetics</i> , 2001, 3, 159-162.	1.4	55
208	Primary Giant Cell Tumor of Soft Tissues. <i>American Journal of Surgical Pathology</i> , 2000, 24, 248-256.	3.7	167
209	Liposarcoma: New entities and evolving concepts. <i>Annals of Diagnostic Pathology</i> , 2000, 4, 252-266.	1.3	302
210	Title is missing!. <i>Applied Immunohistochemistry &amp; Molecular Morphology</i> , 1999, 7, 255.	2.0	4
211	Identification of mitochondria in liver biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1998, 433, 267-273.	2.8	12
212	Primary Liposarcoma of the Skin: A Rare Neoplasm With Unusual High Grade Features. <i>American Journal of Dermatopathology</i> , 1998, 20, 332-338.	0.6	104
213	Fibrosarcomatous ("High-Grade") Dermatofibrosarcoma Protuberans. <i>American Journal of Surgical Pathology</i> , 1998, 22, 576-587.	3.7	360
214	Desmoplastic Small Round Cell Tumors of the Paratesticular Region. <i>American Journal of Surgical Pathology</i> , 1997, 21, 219-225.	3.7	133
215	Extraskeletal Myxoid Chondrosarcoma: An Immunohistochemical Reappraisal of 39 Cases. <i>Applied Immunohistochemistry &amp; Molecular Morphology</i> , 1997, 5, 73-77.	2.0	42
216	Aspiration biopsy cytology of intranodal myofibroblastoma: Case report with immunocytochemical analysis. <i>Diagnostic Cytopathology</i> , 1995, 13, 134-138.	1.0	10

#	ARTICLE	IF	CITATIONS
217	Aspiration biopsy cytology of tubular carcinoma of the breast. <i>Diagnostic Cytopathology</i> , 1994, 11, 146-150.	1.0	14
218	Pancreatic (Acinar) Metaplasia of the Gastric Mucosa. <i>American Journal of Surgical Pathology</i> , 1993, 17, 1134-1143.	3.7	70
219	Aspiration biopsy cytology of malignant papillary breast neoplasms. <i>Diagnostic Cytopathology</i> , 1992, 8, 580-584.	1.0	21